INTRODUCTION {#sec1}
============

More than 1.1 million cases of prostate cancer (PCa) cases were registered per year during the last few years, which represents around 8% of new cases and 15% in men all over the world \[[@cit0001]\]. PCa is the second leading cause of cancer-specific death in the United States and it is estimated that during the following years 26,120 new deaths will be caused by this condition \[[@cit0002]\].

Nowadays, more than 90% of PCa cases are diagnosed in the early stages, which get higher 5 year-overall survival (almost 100%) \[[@cit0002]\]. This is generally suspected by an abnormal digital rectal examination and/or an elevated prostate-specific antigen (PSA) \[[@cit0003]\]. Early detection might significantly reduce related morbidity and increase survival of these patients, this is why urologists need to diagnose and initiate treatment faster to increase the probability of a succesful outcome \[[@cit0004], [@cit0005]\].

Regarding the diagnosis, the prostate biopsy is the gold standard to make the diagnosis and we have two different approaches to perform this procedure: transperineal and transrectal. The latter is the most commonly used nowadays \[[@cit0006]\]. Although transrectal ultrasound-guided (TRUS) prostatic biopsy has been considered a minor procedure, people often experience pain, anxiety and disturbances before, during and after the procedure \[[@cit0007]\]. About 65--90% of men experience pain based on different factors: entering an ultrasound probe in the rectum, the movement of this device, size and geometry of the probe, the insertion of the needle for injecting anesthetics, the biopsy itself, among others \[[@cit0006], [@cit0007], [@cit0008]\].

Pain is the most important problem during this procedure and there are lots of approaches to reduce it and to improve adaptation of these patients; however, there is no consensus about what to choose \[[@cit0009]\].

The European Association of Urology recommend topical anesthesia plus periprostatic nerve bundle block (PPNB) \[[@cit0010]\]; however, there are multiple trials considering other approaches like a single PPNB, only topical gels, combined therapies, among others, additionally, there is some evidence supporting that the most painful moment is the application of the anesthetic \[[@cit0010], [@cit0011]\].

Based on literature, there is no standard of care to this approach and selection depends mainly on clinical condition, experience of the physician and clinical criteria, furthermore, we considered a systematic review to try to elucidate this problem. The purpose of this systematic review was to determine the effectiveness and harms of periprostatic block compared with other interventions in patients with clinically suspected prostate cancer who undergo transrectal biopsy to diminish pain during and after the procedure.

MATERIAL AND METHODS {#sec2}
====================

We performed this review according to the recommendations of the Cochrane Collaboration and following the PRISMA Statement. The PROSPERO registration number is CRD42018094806.

Inclusion criteria {#sec2.1}
------------------

We included only clinical trials which involved male adults over 18 years-old suspected of having prostate cancer based on any of the clinical or biochemical indications and who underwent transrectal prostate biopsy according to standard procedure. The intervention was periprostatic block (injecting an anesthetic solution (bupivacaine 0.25%, lidocaine 1--2% or articaine 1%) on neurovascular bundles on each side of the prostate gland, this has to be guided by ultrasound and identifying the correct position by a hypoechoic bubble) and the comparators were topical anesthetics, sedatives, placebo/no intervention or combined therapies \[[@cit0012], [@cit0013]\].

The primary outcome was perianal or perineal pain (assessed by any validated tool i.e. visual analogue scale (VAS) and serious adverse effects (SAE) (fever, rectal bleeding \>2 days, prostatitis and acute urinary retention) \[[@cit0014]\]. Secondary outcomes were other adverse effects (hematospermia, hematuria, rectal bleeding less than two days) \[[@cit0002]\]. There were no setting or language restrictions. The exclusion criteria were: transperineal biopsy and other conditions that might increase or produce pain during the biopsy.

Information sources {#sec2.2}
-------------------

Literature search was conducted in accordance to the recommended procedure by Cochrane. We used medical subject headings (MeSH), Emtree language, DeCS and text words related in a complete search strategy (Appendix 1). We searched MEDLINE (OVID), EMBASE, LILACS and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to March 2019. To ensure literature saturation, we scanned references from relevant articles identified through the search, conferences, thesis databases, Open Grey, Google scholar and clinicaltrials.gov, among others. We contacted authors by e-mail in case of missing information.

Data collection {#sec2.3}
---------------

We reviewed each reference by title and abstract. Then we scanned full-texts of relevant studies, applied pre-specified inclusion and exclusion criteria and then extracted the data. Disagreements were resolved by consensus and where disagreement could not be solved, a third reviewer was used to dissolve the conflict.

Relevant data were collected in duplicate by using a standardized data extraction sheet that contained the following information: author names, year of publication, title, study design, geographic location, objectives, inclusion and exclusion criteria, number of patients included, losses to follow-up, timing, definition of outcomes (infection), outcomes and association measures and funding source.

Risk of bias {#sec2.4}
------------

The assessment of the risk of bias for each study was made using the Cochrane Collaboration tool for assessing the risk of bias, which covers: sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other biases. We judged the possible risk of bias from extracted information, rated as 'high risk', 'low risk' or 'unclear risk'. We computed a graphic representation of potential bias using RevMan 5.3.

Data analysis / synthesis of results {#sec2.5}
------------------------------------

We performed the statistical analysis in R \[[@cit0015]\] with the command gemtc for a Bayesian network meta-analysis and Review Manager v5.3. For outcomes we reported information about risk differences (RD) with 95% confidence intervals according to the type of variables and we pooled the information with a fixed effect network meta-analysis according to the heterogeneity expected. The results were reported in forest plots of the estimated effects of the included studies with a 95% confidence interval (95% CI). Heterogeneity was evaluated using the I2 test. For the interpretation, it was determined that the values of 25%, 50%, and 75% in the I2 test corresponded to low, medium, and high levels of heterogeneity, respectively.

Assumption of transitivity was plausible and evaluated according to the kind of comparisons and considering the similarity of the distribution of the potential effect modifiers across the different pairwise comparisons. Additionally, for every treatment, we estimated the probability of being at each possible rank to infer the relative ranking of the treatments.

Publication bias {#sec2.6}
----------------

An evaluation was conducted to identify reporting or publication bias using the funnel plot.

Sensitivity analysis {#sec2.7}
--------------------

We performed sensitivity analysis extracting weighted studies and running the estimated effect to find differences.

Geometry of the network {#sec2.8}
-----------------------

We produced network diagrams to show the amount of evidence available for each outcome and the most frequent comparison. The size of the nodes was proportional to the total number of patients allocated to the treatments across all trials and the width of the lines was proportional to the total number of RCTs evaluating the comparisons.

Assessment of inconsistency {#sec2.9}
---------------------------

We evaluated consistency using the node-splitting model through a Bayesian network meta-analysis.

Subgroup analysis {#sec2.10}
-----------------

We tried to perform subgroup analysis based on: age, geographical setting and kind of biopsy, but the information was similar on some variables and so dissimilar in other, therefore we decided against performing it.

RESULTS {#sec3}
=======

Study selection {#sec3.1}
---------------

We found a total of 1299 studies with the search strategies and after eliminating 143 duplicates and those based on title and abstract screening, we finally included 43 studies \[[@cit0010], [@cit0016]--[@cit0057]\] in the qualitative and quantitative analysis ([Figure 1](#f0001){ref-type="fig"}). We updated the search to March 2019 and found 120 additional files, but none of them were relevant to this study (Excluded by title/abstract).

![Flowchart.](CEJU-72-1874-g001){#f0001}

Characteristics of included studies {#sec3.2}
-----------------------------------

A total of 5,885 patients with a mean of 137 patients per study (range 40--430) were included. Seven studies used placebo as the only comparator \[[@cit0016], [@cit0019], [@cit0020], [@cit0029], [@cit0044], [@cit0045], [@cit0052]\], while five used no intervention as the comparator \[[@cit0017], [@cit0021], [@cit0033], [@cit0042], [@cit0055]\].

The indication of biopsy was not clearly described in one single article \[[@cit0051]\] and the most common indication was an abnormal PSA levels and/or suspicious digital rectal exam (DRE) \[[@cit0010], [@cit0016]--[@cit0057]\].

For the evaluation of the results, all the studies used an analogous scale of pain (VAS) that ranges between 0--10 \[[@cit0010], [@cit0016]--[@cit0054], [@cit0056], [@cit0057]\]. The time for the most frequent outcome evaluation was immediately after the biopsy, which was performed in twenty-six studies \[[@cit0017]--[@cit0027], [@cit0029]--[@cit0031], [@cit0033], [@cit0036], [@cit0039], [@cit0040], [@cit0045], [@cit0047], [@cit0048], [@cit0050], [@cit0051], [@cit0053], [@cit0054], [@cit0056]\]. Thirteen studies have a result evaluation during the biopsy \[[@cit0010], [@cit0025], [@cit0032], [@cit0034], [@cit0037], [@cit0041]--[@cit0044], [@cit0049], [@cit0052], [@cit0055], [@cit0057]\], two studies at 15 minutes after the biopsy \[[@cit0016], [@cit0046]\], one study during the insertion of the needle \[[@cit0038]\], another study 20 minutes after \[[@cit0035]\] and one 30 minutes after of biopsy \[[@cit0028]\] (see [Table 1](#t0001){ref-type="table"}).

###### 

Characteristics of included studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                               No. of patients   Participants                                                                                                                                                                                                                                                                            Intervention 1                                                                             Intervention 2                                                   Intervention 3                                                               Intervention 4                                      Outcome assessment
  ----------------------------------------------------------------------------------- ----------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------------- ---------------------------------------------------------------------------- --------------------------------------------------- ----------------------------
  Ozveri et al. (2003) \[[@cit0016]\]                                                 100               Men, elevated total prostate-specific antigen (tPSA) and/or abnormal digital rectal examination (DRE)                                                                                                                                                                                   Periprostatic block (Lidocaine)                                                            Placebo                                                                                                                                                                                           15 min after the procedure

  Walsh et al. (2003) \[[@cit0017]\]                                                  64                Abnormal DRE or an elevated PSA                                                                                                                                                                                                                                                         Periprostatic block (Lidocaine)                                                            No intervention                                                                                                                                                                                   Immediately

  Rodriguez et al. (2003) \[[@cit0018]\]                                              96                Abnormal prostate on digital rectal examination and/or elevated serum prostate specific antigen PSA, some patients have re-biopsy because of a prostatic intraepithelial neoplasia history (PIN), a continuous raised PSA level and a diagnosed cancer in previous prostate resection   Intrarectal gel (Lidocaine)                                                                Periprostatic block (Lidocaine)                                                                                                                                                                   Immediately

  Addla et al. (2003) \[[@cit0019]\]                                                  98                Prescriptions were requested\                                                                                                                                                                                                                                                           Periprostatic block (Lidocaine)                                                            Placebo                                                                                                                                                                                           Immediately
                                                                                                        on a named patient basis at the beginning of each TRUS biopsy list                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Berger et al. (2003) \[[@cit0020]\]                                                 100               Men suspected of having prostate cancer                                                                                                                                                                                                                                                 Periprostatic block (Lidocaine)                                                            Placebo                                                                                                                                                                                           Immediately

  Subjects were included a normal age-specific prostate-specific antigen (PSA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Rodriguez et al. \[[@cit0053]\] (2002)                                              96                Abnormal DRE or an elevated PSA                                                                                                                                                                                                                                                         Intrarectal gel (Lidocaine)                                                                Periprostatic block (Lidocaine)                                                                                                                                                                   Immediately

  Stirling et al. (2002) \[[@cit0021]\]                                               100               Referred for transrectal ultrasound from who informed consent was obtained were eligible                                                                                                                                                                                                No intervention                                                                            Periprostatic block (Lidocaine)                                                                                                                                                                   Immediately

  Lynn et al. (2002) \[[@cit0022]\]                                                   86                Abnormal PSA level (\>4 ng/mL) and/or an abnormal DRE, and prostatic biopsy for the first time                                                                                                                                                                                          Periprostatic block (Lidocaine)                                                            Intrarectal gel (Lidocaine)                                      Placebo gel                                                                  Placebo                                             Immediately

  Stirling et al. (2002) \[[@cit0023]\]                                               150               Men requiring biopsy of the prostate                                                                                                                                                                                                                                                    No intervention                                                                            Intrarectal gel (Lidocaine)                                      Periprostatic block (Lidocaine)                                                                                                  Immediately

  Hiros et al. (2010) \[[@cit0024]\]                                                  90                Abnormal PSA level (\>4 ng/mL) and/or an abnormal DRE, and prostatic biopsy for the first time                                                                                                                                                                                          Periprostatic block (Lidocaine)                                                            Intrarectal gel (Voltaren)                                       Placebo gel                                                                                                                      Immediately

  Kim et al. (2011) \[[@cit0025]\]                                                    430               Patients who visited the department of urology                                                                                                                                                                                                                                          Periprostatic nerve block with 1% lidocaine                                                Acetaminophen 650 mg,                                            EMLA cream                                                                                                                       During biopsy

  Song et al. \[[@cit0056]\] (2004)                                                   90                Abnormal DRE, level PSA\>4 ng                                                                                                                                                                                                                                                           Intrarectal gel (Lidocaine)                                                                Periprostatic block (Lidocaine)                                  Placebo                                                                                                                          Immediately

  Yun et al. \[[@cit0057] \] (2006)                                                   250               Increased PSA with or without abnormal digital rectal examination, 2) with lesion suspected malignancy on TRUS                                                                                                                                                                          Lidocaine gel intrarectal+PNB                                                              Perianal block (Lidocaine)                                                                                                                                                                        During biopsy

  Manikandan et al. (2003) \[[@cit0026]\]                                             235               Abnormal PSA levels and/or suspicious DRE                                                                                                                                                                                                                                               No intervention                                                                            Periprostatic block (Lidocaine)                                  Sedative (Entonox)                                                                                                               Immediately

  Obek \[[@cit0027]\] et al. (2004)                                                   300               Abnormal PSA levels and/or suspicious DRE                                                                                                                                                                                                                                               No intervention                                                                            Periprostatic block (Lidocaine)                                  Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine)                Tramadol infused intravenously in 30 minutes at a   Immediately

  dose of 1.5 mg/kg in 100 cc saline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Mallick et al. (2004) \[[@cit0028]\]                                                328               Abnormal digital rectal prostate examination or transrectal ultrasound scan and/or elevated prostate specific antigen (PSA) (greater than to 4 ng/ml).                                                                                                                                  Intrarectal gel (Lidocaine)                                                                Periprostatic block (Lidocaine)                                                                                                                                                                   30 min

  Vanni et al. (2004) \[[@cit0029]\]                                                  40                Elevated PSA levels and/or suspicious DRE                                                                                                                                                                                                                                               Periprostatic block (Lidocaine)                                                            Placebo                                                                                                                                                                                           Immediately

  Trucchi et al. (2005) \[[@cit0030]\]                                                60                Elevated prostate-specific antigen (PSA) level and its derivates (total and free PSA, free/total PSA ratio, PSA density, PSA velocity), abnormal digital rectal examination (DRE), abnormal transrectal sonography                                                                      No intervention                                                                            Intrarectal gel (Lidocaine)                                      Periprostatic block (Lidocaine)                                              --                                                  Immediately

  Kravchick et al. (2005) \[[@cit0031]\]                                              114               Abnormal digital rectal examination findings and/or an elevated prostate-specific antigen (PSA) level (4 ng/mL or greater)                                                                                                                                                              Intrarectal gel (Lidocaine)                                                                Intrarectal gel (DMSO + Lidocaine)                               Perianal block (Lidocaine)                                                   Periprostatic block (Lidocaine)                     Immediately

  Ragavan et al. (2005) \[[@cit0032]\]                                                165               Increased prostate specific antigen (PSA) with or without abnormal digital rectal examination                                                                                                                                                                                           Periprostatic block (Lidocaine)                                                            Diclofenac suppository                                           Periprostatic block (Lidocaine) + Diclofenac suppository                                                                         During biopsy

  Feltes Ochoa et al. (2006) \[[@cit0033]\]                                           131               Abnormal PSA level (\>4 ng/mL) and/or an abnormal DRE                                                                                                                                                                                                                                   Periprostatic block (Bupivacaine)                                                          No intervention                                                                                                                                                                                   Immediately

  Song et al. (2006) \[[@cit0034]\]                                                   90                Abnormal digital rectal examination and/or serum prostate-specific antigen (PSA) concentrations of 4 ng/mL or higher.                                                                                                                                                                   Intrarectal gel (Lidocaine)                                                                Periprostatic block (Lidocaine)                                  Placebo                                                                                                                          During biopsy

  Yun et al. (2007) \[[@cit0035]\]                                                    250               Abnormal digital rectal examination, with lesion                                                                                                                                                                                                                                        Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine)                              Periprostatic block (Lidocaine)                                                                                                                                                                   20 min. After biopsy

  suspected malignancy on TRUS with or without abnormal digital rectal examination,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Giannarini et al. (2009) \[[@cit0010]\]                                             280               Increased serum PSA (4 ng/ml or greater),                                                                                                                                                                                                                                               Periprostatic block (Lidocaine) + Intrarectal cream (Lidocaine + Prilocaine)               Intrarectal cream (Lidocaine +Prilocaine)                        Periprostatic block (Lidocaine)                                              No intervention                                     During biopsy

  and/or abnormal digital rectal examination or TRUS findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Izol et al. (2012) \[[@cit0036]\]                                                   100               Abnormal finding during the digital examination and/or elevated serum PSA levels higher than 2.5 ng/mL                                                                                                                                                                                  No intervention                                                                            Periprostatic block (Lidocaine)                                  Intrarectal gel (Lidocaine)                                                  Sedative (Midazolam + Fentanil)                     Immediately

  Lunacek et al. (2014) \[[@cit0054]\]                                                123               People with suspected PCa without active prostatitis underwent TRUS-guided biopsy                                                                                                                                                                                                       Intrarectal gel (Lidocaine)                                                                Periprostatic block (Lidocaine)                                  Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine)                                                                    Immediately

  Griwan et al. (2012) \[[@cit0037]\]                                                 60                Patients with elevated prostate-specific antigen (PSA) levels (\>4 ng/mL) and abnormal results on digital rectal examination (DRE),                                                                                                                                                     Diclofenac patch 100mg                                                                     Periprostatic block (Lidocaine)                                  No intervention                                                                                                                  During biopsy

  Ozok et al. (2010) \[[@cit0038]\]                                                   100               Patients with prostate-specific antigen (PSA) above the level of 2.5 ng/ml and/or with abnormal digital rectal examination (DRE) findings were included in the study                                                                                                                    Periprostatic block (Lidocaine)                                                            Periprostatic block (Lidocaine) + Tramadol hydrochloride 50 mg   Periprostatic block (Lidocaine) + Intramuscular Midazolam                    Placebo                                             Pain during needle

  Sataa et al. (2010) \[[@cit0039]\]                                                  100               Less than 70 years of age and in whom prostate biopsy was indicated for a prostate suspected malignancy to the rectal examination and / or an increase in the level of the specific antigen prostate (PSA) \>3 ng/ml                                                                    Intrarectal gel (Lidocaine)                                                                Periprostatic block (Lidocaine)                                  Placebo gel                                                                  --                                                  Immediately

  Szlauer et al. (2008) \[[@cit0040]\]                                                100               Indications for prostate biopsy included an abnormal digital rectal examination and/or an elevated serum PSA level                                                                                                                                                                      Intrarectal gel (60 mg lidocaine 2h)                                                       Intrarectal gel (120 mg lidocaine 1h)                            Intrarectal gel (120 mg lidocaine 2h)                                        Periprostatic block (Lidocaine)                     Immediately

  Raber et al. (2008) (41)                                                            300               Abnormally elevated prostate-specific antigen (PSA) values or suspicious digital rectal exam (DRE) results                                                                                                                                                                              Periprostatic block (Lidocaine)                                                            Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine)    Placebo                                                                                                                          During biopsy

  Jones et al. (2003) \[[@cit0042]\]                                                  60                Men requiring biopsy of the prostate                                                                                                                                                                                                                                                    Periprostatic block (Lidocaine)                                                            No intervention                                                                                                                                                                                   Immediately

  Turgut et al. (2006) \[[@cit0003]\]                                                 93                Suspicious digital rectal examination (DRE), abnormally elevated serum prostate-specific antigen (PSA) level or abnormal TRUS findings referred                                                                                                                                         Sedative (Midazolam)                                                                       Periprostatic block (Lidocaine)                                  No intervention                                                                                                                  Immediately

  Raber et al. (2008) (41)                                                            73                Abnormal prostate on digital rectal examination and/or elevated prostate specific antigen (PSA\> 4 ng/ml)                                                                                                                                                                               Periprostatic block (Lidocaine)                                                            Placebo                                                                                                                                                                                           Immediately

  Jones et al. (2003) \[[@cit0042]\]                                                  126               Abnormal digital rectal examination (EDR) and/or elevated prostate specific antigen (PSA)                                                                                                                                                                                               Periprostatic block (Lidocaine)                                                            No intervention                                                                                                                                                                                   Pain following biopsy

  Nambirajan et al. (2004) \[[@cit0045]\]                                             96                Abnormal digital rectal examination (DRE) or elevated PSA                                                                                                                                                                                                                               Periprostatic block (Lidocaine)                                                            Placebo                                                                                                                                                                                           Immediately

  Gurbuz et al. (2010) \[[@cit0046]\]                                                 100               Elevated prostate-specific antigen (PSA) levels                                                                                                                                                                                                                                         No intervention                                                                            Perianal block (Lidocaine)                                       Periprostatic block (Lidocaine)                                              Intrarectal cream (Lidocaine + Prilocaine)          15 min

  Park et al. (2005) \[[@cit0047]\]                                                   61                Patients with a negative pathology after an initial sextant biopsy, with no sedatives or analgesia, were rebiopsied using the 12 extended biopsy technique.                                                                                                                             Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine)                              Perianal block (Lidocaine)                                       Intrarectal gel (Lidocaine)                                                                                                      Immediately

  Basar et al. (2005) \[[@cit0048]\]                                                  80                Patients with elevated prostate-specific antigen (PSA) levels or with normal PSA values but with prostate nodules on digital rectal examination (DRE) were included                                                                                                                     Placebo cream                                                                              Intrarectal cream (Lidocaine + Prilocaine)                       Periprostatic block (Prilocaine)                                             Periprostatic block (Lidocaine)                     Immediately

  Cantiello et al. (2009) \[[@cit0049]\]                                              200               Abnormal DRE findings, or an increased PSA level with or without abnormal DRE findings, or lesions suspicious for malignancy on TRUS with or without an abnormal DRE                                                                                                                    Periprostatic block (Lidocaine + Naropine)                                                 Periprostatic block (Antroline)                                                                                                                                                                   During biopsy

  Kumar et al. (2012) \[[@cit0050]\]                                                  240               All patients with indication for biopsy                                                                                                                                                                                                                                                 Periprostatic block (Lidocaine)                                                            Intrarectal cream (Lidocaine + Prilocaine)                       Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine + Prilocaine)   --                                                  Immediately

  Dalva et al. (2013) \[[@cit0051]\]                                                  90                NA                                                                                                                                                                                                                                                                                      Perianal lidocaine\--prilocaine cream (EMLA, 5 gr) + periprostatic nerve block lidocaine   Periprostatic block (Lidocaine)                                                                                                                                                                   Immediately

  Wu et al. (2001) \[[@cit0052]\]                                                     40                All patients had laboratory indications for prostate biopsy (eg, elevated PSA level of 4.0 indications for prostate biopsy (eg, elevated PSA level of 4.0                                                                                                                               Periprostatic block (Lidocaine)                                                            Placebo                                                                                                                                                                                           During biopsy
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Summary of network geometry {#sec3.3}
---------------------------

Placebo/no intervention vs. periprostatic block only was the most frequent comparison, it was found in 13 studies \[[@cit0016]--[@cit0021], [@cit0029], [@cit0033], [@cit0042], [@cit0044], [@cit0045], [@cit0052], [@cit0055]\]. We found nine studies with the comparison between intrarectal gel (lidocaine) vs. periprostatic block (lidocaine) \[[@cit0018], [@cit0027], [@cit0028], [@cit0035], [@cit0040], [@cit0047], [@cit0053], [@cit0054], [@cit0057]\] and seven studies with intrarectal gel (lidocaine) vs. placebo/no intervention \[[@cit0022], [@cit0023], [@cit0030], [@cit0034], [@cit0039], [@cit0041], [@cit0056]\].

Two studies followed the comparison with intrarectal gel (lidocaine) vs. periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine) \[[@cit0047], [@cit0054]\], while four studies used periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine) vs. periprostatic block (lidocaine) \[[@cit0010], [@cit0035], [@cit0050], [@cit0051]\].

Three studies had the following comparisons: 1. placebo gel vs. periprostatic block (lidocaine); 2. sedative vs. periprostatic block (lidocaine); 3. placebo/no intervention vs. periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine); 4. intrarectal gel (lidocaine) vs. placebo gel; 5. sedative vs. placebo/no intervention (see [Figure 2](#f0002){ref-type="fig"}).

![Network plot for outcome pain.](CEJU-72-1874-g002){#f0002}

Yun 2016 was excluded from the network analysis since it had only one arm.

Risk of bias {#sec3.4}
------------

All of the studies were classified as low risk of bias in the following issues: incomplete outcome data, selective reporting and other bias. On the contrary, we found mostly unclear risk of bias in: random sequence generation, allocation concealment, blinding of participants and personnel and blinding of outcome assessment.

Stirling 2002, Stirling 2002a and Szlauer 2008 \[[@cit0021], [@cit0023], [@cit0040]\] had high risk of bias in blinding of participants and personnel since they had incomplete masking, while some groups were aware of intervention. Wu 2001 \[[@cit0052]\], had a high risk of bias in the random sequence generation since it had randomization based on inappropriate tools.

Studies like Addla 2003, Kravchick 2005, Lynn 2002 and Ragavan 2005 were classified as high quality (low risk of bias) since they only had one issue on the unclear risk of bias \[[@cit0019], [@cit0022], [@cit0031], [@cit0032]\] (see [Figure 3](#f0003){ref-type="fig"}).

![Risk of bias within studies.](CEJU-72-1874-g003){#f0003}

![Risk of bias across studies.](CEJU-72-1874-g004){#f0004}

Exploration for inconsistency and ranking {#sec3.5}
-----------------------------------------

For the primary outcome and the node-splitting model we found that the following comparisons were consistent, but some of them were heterogeneous: periprostatic block A (lidocaine injection) versus combined \[(periprostatic block (lidocaine) + intrarectal gel (lidocaine + prilocaine) (I2 = 99%; inconsistency p value = 0.12); periprostatic block A versus topical (intrarectal gel \[lidocaine)\] (I2=99%; inconsistency p value = 0.38); combined versus placebo / no intervention (I2 = 45%; inconsistency p value = 0.74); combined versus topical (I2 = 99%; inconsistency p value = 0.35); placebo gel versus placebo / no intervention (I2 = 0%; inconsistency p value = 0.33); placebo / no intervention versus topical (I2 = 90%; inconsistency p value = 0.18); sedative versus topical (I2 = 21%; inconsistency p value = 0.3) ([Table 2](#t0002){ref-type="table"}). Ranks were higher for placebo and topical interventions (see [Figure 4](#f0005){ref-type="fig"}).

###### 

Results for consistent comparisons

  Comparison                                                                                                                                      
  -------------------------------------------------------------------------------------------------------------- -------- ------- ------- ------- ---------
  Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine+Prilocaine) vs. Periprostatic block (Lidocaine)   Direct   -1.4    -2.5    -0.36   0.1285
  Indirect                                                                                                       0.99     -2      4               
  Network                                                                                                        -0.9     -1.9    0.074           
  Intrarectal gel (Lidocaine) vs. Periprostatic block (Lidocaine)                                                Direct   0.82    0.099   1.6     0.3869
  Indirect                                                                                                       -0.71    -4.2    2.7             
  Network                                                                                                        0.77     0.14    1.4             
  Placebo/No intervention vs. Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine+Prilocaine)           Direct   2.9     1.2     4.7     0.7479
  Indirect                                                                                                       3.3      1.9     4.7             
  Network                                                                                                        3        1.9     4               
  Intrarectal gel (Lidocaine) vs. Periprostatic block (Lidocaine) + Intrarectal gel (Lidocaine+Prilocaine)       Direct   0.9     -0.38   2.2     0.35525
  Indirect                                                                                                       1.8      0.4     3.2             
  Network                                                                                                        1.7      0.64    2.7             
  Placebo/No intervention vs. Placebo gel                                                                        Direct   -0.51   -3.4    2.4     0.3387
  Indirect                                                                                                       1.2      -0.92   3.4             
  Network                                                                                                        0.19     -1.4    1.8             
  Intrarectal gel (Lidocaine) vs. Placebo/No intervention                                                        Direct   -1      -1.9    -0.08   0.18465
  Indirect                                                                                                       -2       -3.2    -0.85           
  Network                                                                                                        -1.3     -2.1    -0.6            
  Intrarectal gel (Lidocaine) vs. Sedative                                                                       Direct   2.7     -0.82   6.2     0.3
  Indirect                                                                                                       0.6      -1.3    2.5             
  Network                                                                                                        0.96     -0.67   2.6             

![Graphical representation of ranks.](CEJU-72-1874-g005){#f0005}

Outcome: pain {#sec3.6}
-------------

After running the Bayesian Network meta-analysis, we found that the periprostatic block (lidocaine), combined therapy \[periprostatic block (lidocaine) + intrarectal gel \[lidocaine + prilocaine)\]; periprostatic block (lidocaine) + tramadol hydrochloride 50 mg; sedative and intrarectal gel (lidocaine) lowered the pain when compared with placebo. Additionally, any kind of placebo and intrarectal gel increased the pain when compared with the periprostatic block (lidocaine) ([Figure 5](#f0006){ref-type="fig"}).

![Interventions compared against Placebo.](CEJU-72-1874-g006){#f0006}

![Interventions compared against Periprostatic block A.](CEJU-72-1874-g007){#f0007}

Mixed treatment comparisons {#sec3.7}
---------------------------

As we stated before, the following comparisons were consistent on the network. For the comparisons: periprostatic block A versus topical \[intrarectal gel (lidocaine)\] and combined versus topical, we found that topical intervention increases pain. Similar to the placebo in the comparison: combined versus placebo / no intervention. On the otherside, there was decreased pain for the topical in the comparison: placebo/no intervention versus topical (see [Table 2](#t0002){ref-type="table"}). There were no significant differences for the other comparisons.

Secondary outcomes {#sec3.8}
------------------

The secondary results obtained included adverse effects defined as fever, rectal bleeding \>2 days, prostatitis, urinary retention and death \[[@cit0027]\]. The following studies reported some of these events.

In the studies comparing periprostatic plexus block vs. placebo \[[@cit0016], [@cit0020]\], intrarectal gel vs. periprostatic plexus block vs. placebo and the study of intrarectal gel vs. periprostatic plexus block vs. placebo, fever was not reported as an adverse event during the follow-up period. In the study of placebo intrarectal cream vs. intrarectal cream vs. periprostatic plexus block \[[@cit0048]\] and in periprostatic block vs. intrarectal gel (Voltaren) vs. intrarectal gel placebo, no serious adverse events were reported \[[@cit0024]\].

In the study where the groups non-intervention vs. periprostatic plexus block vs. periprostatic plexus block in combination with intrarectal gel vs. tramadol infusion were compared, the following were reported in intervention group 1:1 fever event; group two: 1 event of urinary retention; and group three: one event of fever and six events of urinary retention \[[@cit0027]\].

In the study of intrarectal gel (lidocaine) vs. intrarectal gel (DMSO + lidocaine) vs. perianal block vs. periprostatic block without specification of belonging to a specific intervention, it was reported that 10 days after the biopsy, two patients presented with fever, and there was one urinary retention event \[[@cit0031]\].

In the comparison the study between periprostatic plexus block vs. intrarectal diclofenac suppository vs. periprostatic plexus block in combination with diclofenac suppository, fever occurred in 1, 2 and 0 patients, respectively, in each intervention \[[@cit0032]\].

In the block of periprostatic plexus vs. intrarectal gel vs. placebo, intervention group 1 presented with three events of fever and urinary retention; intervention group 2: two events of fever; and intervention group 3: two events of fever and urinary retention \[[@cit0041]\].

In the comparison of periprostatic plexus block vs. placebo, the placebo group presented with one infection event without specification that required hospital admission \[[@cit0045]\].

In the intervention study of periprostatic plexus block in combination with intrarectal gel vs. placebo vs. intrarectal gel, there was one event of urinary retention in group 1; none of the groups presented fever \[[@cit0047]\].

Finally, in the comparison of periprostatic plexus block (lidocaine + naropin) vs. periprostatic plexus block (antrolin), there was one event of urinary retention and fever in both groups \[[@cit0049]\].

DISCUSSION {#sec4}
==========

To our knowledge, this is the first systematic review and online meta-analysis of clinical trials published to date in which we attempted to determine the efficacy of periprostatic block to prevent pain in transrectal prostate biopsy. We performed multiple comparisons between the analgesic therapies used to relieve pain during transrectal prostate biopsy.

Our findings showed that any type of intervention was significantly superior to the placebo to prevent pain. In addition, our results showed that patients undergoing transrectal prostatic biopsy with periprostatic block or combination therapy (periprostatic block + intrarectal gel) had significantly lower pain scores than patients treated only with topical intervention (intrarectal gel). Intrarectal gel and periprostatic block did not show significant differences.

In contrast with these results, certain published randomized controlled trials (RCTs), such as Ingberg in 2010, supported the idea that the pain experienced during transrectal prostate biopsy was mild and did not decrease significantly with periprostatic block, and they noted that the pain of the injection itself was similar to the pain of the biopsies. They concluded that pain from transrectal prostate biopsy was well tolerated without requiring anesthesia \[[@cit0058]\] and Wu et al. did not find significant differences between the intervention groups with or without periprostatic plexus block with respect to VAS pain scores at any time \[[@cit0052]\]. However, some of the limitations of these studies include the size of the sample and the evaluation of pain at the actual moment of the procedure.

Supporting the results obtained in this review, different studies indicate that there are significant differences in the perception of pain during the transrectal prostate biopsy, which can be seen in the study by Ozvery et al., who found that approximately 50% of patients who were subjected to transrectal prostate biopsy who did not receive the injection of lidocaine as an intrarectal block had VAS pain scores ranging from moderate severity to intolerable. In 2011, Ozvery and Izol et al. demonstrated that patient comfort was better and that it was possible to obtain lower pain scores with periprostatic plexus block or sedoanalgesia. In 2003, Izol and Addla suggested that local anesthesia for TRUS biopsy was simple and well tolerated and could significantly reduce the pain associated with the procedure, recommending its use as part of the standard TRUS prostate biopsy \[[@cit0019], [@cit0036]\].

Among the strengths of our review was the quality of the search strategies designed for each database, which were specific for the detection of records related to the review, along with the inclusion of a sizeable number of available studies. However, some of the limitations are based on the risk of unclear bias regarding the generation of random sequences, concealment of allocation, blinding of participants and staff and blinding of the evaluation of results, which was not possible to determine in the complete review of the studies. This limitation does not necessarily indicate poor or good methodological quality. However, it could lead to an underestimation of quality because the best tool available to assess quality is the Cochrane Collaboration tool, which requires an appropriate report to properly stratify the studies. However, the studies generally had a low risk of bias with respect to incomplete outcome data, selective reporting and other biases.

Only three studies, Stirling 2002, Stirling 2002a and Szlauer 2008 \[[@cit0021], [@cit0023], [@cit0040]\], blinded the participants and staff; the others had incomplete masking, or some groups were aware of the intervention to which they were going to be submitted, which generated a high risk of blinding bias for these clinical trials.

Finally, this review was performed to answer a question related to a urological procedure commonly performed in clinical practice, based on pre-established and standardized indications, due to the indispensable diagnostic need, as PCa is a presently prevalent disease. Being such a useful procedure, it is important to ask the question about the acceptability or not of the procedure as a consequence of the pain inherent to this study. The pain associated with prostate biopsy is a complex phenomenon with psychosocial and physical attributes, which include the threshold of an individual\'s innate pain, pre-procedure anxiety, fear of a possible diagnosis of cancer and social inhibition towards the rectal exam \[[@cit0018]\], factors that could cause the patient to delay having the biopsy even, when its requirement is of vital importance.

Therefore, according to the findings in this review, we recommend the use of periprostatic block alone or in combination with topical intrarectal analgesia or sedation as part of the standard TRUS prostate biopsy. It should be noted that sedation as analgesia during the study is a field that has been little evaluated because of the ease of performing a periprostatic block in the ambulatory practice of biopsy, a method worthy of future studies.

Despite recommending this intervention, it is suggested to conduct clinical trials with larger samples and better methodological quality to improve the recommendations derived from this systematic review and meta-analysis.

CONCLUSIONS {#sec5}
===========

Periprostatic plexus block in transrectal ultrasound-guided prostatic biopsy, alone or in combination with intrarectal analgesia or sedation, is an effective method to reduce the pain inherent to the performance of the procedure in comparison with placebo or intrarectal analgesia alone. However, more high-quality trials are needed to support this conclusion and recommendation.
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